BLOG

psych

MindMed Begins Phase 3 Emerge Study of MM120 in Patients With Major Depressive Disorder

MindMed recently announced that the first patient has been dosed in its phase 3 Emerge study evaluating MM120 ODT for treatment of major depressive disorder (MDD). MM120 ODT is a proprietary, pharmaceutically optimized form of lysergic acid diethylamide (LSD).